/ARCT
ARCT Stock - Arcturus Therapeutics Holdings Inc.
Healthcare|BiotechnologyNASDAQ
$6.53+1.56%
+$0.10 (+1.56%) • Dec 19
52
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.36
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+584.1%upside
Target: $44.67
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ARCT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$6.46 – $6.60
TARGET (TP)$44.67
STOP LOSS$6.01
RISK/REWARD1:73.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.10
52W High$24.17
52W Low$5.85
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $138.39M | $157.75M | $205.75M | $12.36M | $9.54M |
| Gross Profit | $138.39M | $157.75M | $205.75M | $12.36M | $-46,407,000 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | -486.5% |
| Operating Income | $-95,669,000 | $-78,205,000 | $12.18M | $-202,852,000 | $-71,524,000 |
| Net Income | $-80,941,000 | $-29,725,000 | $9.35M | $-203,674,000 | $-72,148,000 |
| Net Margin | -58.5% | -18.8% | 4.5% | -1648.0% | -756.3% |
| EPS | $-3.00 | $-1.12 | $0.35 | $-7.74 | $-3.55 |
Company Overview
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
8
50%
Hold / Neutral
6
38%
Sell / Underperform
2
13%
Analyst Consensus🟡 Mixed
8 Bullish8 Neutral/Bearish
Price Targets
$40
Average Target
↑ 510.6% Upside
Now
$12
Low
$40
Average
$90
High
Based on 16 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 24th 2025 | H.C. Wainwright | Downgrade | Neutral | $12 |
| October 23rd 2025 | Citigroup | Downgrade | Neutral | $12 |
| October 22nd 2025 | Guggenheim | Downgrade | Neutral | - |
| September 4th 2025 | H.C. Wainwright | Resumed | Buy | $60 |
| May 28th 2025 | Scotiabank | Initiation | Sector Outperform | $32 |
| January 28th 2025 | BTIG Research | Initiation | Buy | $41 |
| August 12th 2024 | Leerink Partners | Initiation | Outperform | $70 |
| December 13th 2023 | Canaccord Genuity | Initiation | Buy | $90 |
| July 24th 2023 | William Blair | Initiation | Outperform | $71 |
| May 11th 2023 | H.C. Wainwright | Upgrade | Buy | $51← $19 |
| November 14th 2022 | Wells Fargo | Resumed | Overweight | $35 |
| November 10th 2022 | Robert W. Baird | Downgrade | Underperform | $18 |
| November 3rd 2022 | Citigroup | Upgrade | Buy | $35← $22 |
| November 2nd 2022 | Barclays | Upgrade | Equal Weight | $25← $16 |
| August 10th 2022 | Raymond James | Downgrade | Underperform | - |
Earnings History & Surprises
ARCTBeat Rate
67%
Last 18 quarters
Avg Surprise
-99.1%
EPS vs Estimate
Beats / Misses
12/6
Last 12 quarters
Latest EPS
$-0.49
Q4 2025
EPS Surprise History
Q1 24
+81.1%
$-0.32vs$-1.69
Q2 24
+14.5%
$-1.00vs$-1.17
Q3 24
+65.4%
$-0.64vs$-1.85
Q4 24
+62.9%
$-0.26vs$-0.70
Q1 25
-236.4%
$-1.11vs$-0.33
Q2 25
+67.1%
$-0.52vs$-1.58
Q3 25
+69.4%
$-0.34vs$-1.11
Q4 25
+38.7%
$-0.49vs$-0.80
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 5, 2026 | $-0.87 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.80 | $-0.49 | +38.7% | ✓ BEAT |
Q3 2025 | Aug 11, 2025 | $-1.11 | $-0.34 | +69.4% | ✓ BEAT |
Q2 2025 | May 12, 2025 | $-1.58 | $-0.52 | +67.1% | ✓ BEAT |
Q1 2025 | Mar 6, 2025 | $-0.33 | $-1.11 | -236.4% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.70 | $-0.26 | +62.9% | ✓ BEAT |
Q3 2024 | Aug 5, 2024 | $-1.85 | $-0.64 | +65.4% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-1.17 | $-1.00 | +14.5% | ✓ BEAT |
Q1 2024 | Mar 7, 2024 | $-1.69 | $-0.32 | +81.1% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-1.79 | $-0.61 | +65.9% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $0.09 | $-1.98 | -2300.0% | ✗ MISS |
Q2 2023 | May 9, 2023 | $2.92 | $0.88 | -69.9% | ✗ MISS |
Q1 2023 | Mar 28, 2023 | $0.98 | $4.43 | +352.0% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-2.01 | $-1.33 | +33.8% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-1.84 | $-0.82 | +55.4% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $-1.29 | $-1.94 | -50.4% | ✗ MISS |
Q1 2022 | Feb 28, 2022 | $-1.77 | $-1.47 | +16.9% | ✓ BEAT |
Q4 2021 | Nov 8, 2021 | $-1.40 | $-2.05 | -46.4% | ✗ MISS |
Q3 2021 | Aug 9, 2021 | $-1.99 | $-2.07 | -4.0% | ✗ MISS |
Latest News
Citigroup Maintains Neutral on Arcturus Therapeutics, Lowers Price Target to $9
➖ NeutralBenzinga•Nov 13, 2025, 08:05 PM•Also:
Piper Sandler Maintains Overweight on Arcturus Therapeutics, Lowers Price Target to $72
📈 PositiveBenzinga•Nov 11, 2025, 05:19 PM
HC Wainwright & Co. Maintains Neutral on Arcturus Therapeutics, Lowers Price Target to $9
➖ NeutralBenzinga•Nov 11, 2025, 04:27 PM
Arcturus Therapeutics Q3 EPS $(0.49) Beats $(0.90) Estimate, Sales $17.151M Miss $21.196M Estimate
📈 PositiveBenzinga•Nov 10, 2025, 09:01 PM
HC Wainwright & Co. Downgrades Arcturus Therapeutics to Neutral, Lowers Price Target to $12
📉 NegativeBenzinga•Oct 24, 2025, 10:44 AM•Also:
Citigroup Downgrades Arcturus Therapeutics to Neutral, Lowers Price Target to $12
📉 NegativeBenzinga•Oct 23, 2025, 04:54 PM•Also:
BTIG Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $23
📈 PositiveBenzinga•Oct 22, 2025, 05:42 PM
Guggenheim Downgrades Arcturus Therapeutics to Neutral
➖ NeutralBenzinga•Oct 22, 2025, 03:29 PM
Arcturus falls after mid-stage study data for cystic fibrosis treatment
📉 NegativeSeeking Alpha•Oct 22, 2025, 01:32 PM
Arcturus Therapeutics Holdings shares are trading lower. The company announced interim results from its ongoing Phase 2 clinical trial of ARCT-032.
📉 NegativeBenzinga•Oct 22, 2025, 01:29 PM
Arcturus Announces Interim Results From Ongoing Phase 2 Clinical Trial Of ARCT-032, Investigational Inhaled mRNA Therapy For People With Cystic Fibrosis
➖ NeutralBenzinga•Oct 22, 2025, 11:34 AM
HC Wainwright & Co. Assumes Arcturus Therapeutics at Buy, Announces Price Target of $60
📈 PositiveBenzinga•Sep 4, 2025, 11:25 AM
Frequently Asked Questions about ARCT
What is ARCT's current stock price?
Arcturus Therapeutics Holdings Inc. (ARCT) is currently trading at $6.53 per share. The stock has moved +1.56% today.
What is the analyst price target for ARCT?
The average analyst price target for ARCT is $44.67, based on 1 analyst.
What sector is Arcturus Therapeutics Holdings Inc. in?
Arcturus Therapeutics Holdings Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ARCT's market cap?
Arcturus Therapeutics Holdings Inc. has a market capitalization of $0.18 billion, making it a small-cap company.
Does ARCT pay dividends?
No, Arcturus Therapeutics Holdings Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACHV
Achieve Life Sciences, Inc.
$4.32
Mkt Cap: $0.2B
AVIR
Atea Pharmaceuticals, Inc.
$3.14
Mkt Cap: $0.2B
FHTX
Foghorn Therapeutics Inc.
$5.24
Mkt Cap: $0.3B
HUMA
Humacyte, Inc.
$1.11
Mkt Cap: $0.2B
IMRX
Immuneering Corporation
$5.65
Mkt Cap: $0.2B
SGMT
Sagimet Biosciences Inc.
$6.28
Mkt Cap: $0.2B
TRDA
Entrada Therapeutics, Inc.
$10.98
Mkt Cap: $0.4B
VNDA
Vanda Pharmaceuticals Inc.
$6.75
Mkt Cap: $0.4B
VYGR
Voyager Therapeutics, Inc.
$4.00
Mkt Cap: $0.2B
ZURA
Zura Bio Limited
$4.27
Mkt Cap: $0.3B
Explore stocks similar to ARCT for comparison